Effect of the Combination of Pterostilbene Cocrystal With Silybin and Nicotinamide Riboside on Exercise-Induced Oxidative Stress

NCT ID: NCT07024966

Last Updated: 2025-08-27

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 14 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-08-01
• Study Completion Date: 2025-11-30

Brief Summary

This study aims to evaluate the effects of the dietary supplement ccPT-SIL-NR, which contains pterostilbene (ccPT), silybin (SIL), and nicotinamide riboside (NR), on oxidative stress markers after a high-intensity exercise session. The primary objective is to assess changes in blood malondialdehyde (MDA) levels.

Secondary objectives include evaluating the effects on oxidative DNA damage (8-OHdG), lipid peroxidation (F2-isoprostanes), total antioxidant capacity (FRAP assay), glutathione ratio (GSH/GSSG), antioxidant enzyme activity (SOD, CAT, GPx), inflammatory markers (hsCRP, MCP-1, IL-6), muscle damage markers (LDH, CK), cortisol levels, renal function (creatinine), and gene expression patterns through transcriptomic analysis.

The study will include 14 healthy male participants in a randomized, tripple-blind, placebo-controlled, crossover design. Each participant will receive both the ccPT-SIL-NR supplement and placebo for 14 days each, separated by a washout period of at least one week. A high-intensity exercise test will be performed at the end of each supplementation period. Total study duration per participant will be a minimum of 6 weeks.

Detailed Description

This study aims to evaluate the effect of a nutritional supplement combining pterostilbene, silybin, and nicotinamide riboside on oxidative stress induced by high-intensity exercise. Oxidative stress occurs when there is an imbalance between the production of reactive oxygen species and the body's ability to counteract their harmful effects. High-intensity physical activity is known to increase oxidative stress, potentially leading to cellular damage and inflammation. The supplement under investigation has shown antioxidant properties in preclinical models, and this trial seeks to explore its efficacy in humans. The trial is a randomized, triple-blind, placebo-controlled, and crossover study. Fourteen healthy, physically active men aged 18-50 will be recruited. Each participant will take either the supplement or placebo twice daily for 14 days, followed by a treadmill exercise session at 80% of their VO₂ max. After a washout period, participants will switch treatments and repeat the protocol. Blood and urine samples will be collected both at baseline (prior to supplement intake and without any physical activity) and after the exercise test to evaluate markers of oxidative stress, inflammation, muscle damage, and antioxidant capacity. The main outcome is the change in plasma levels of malondialdehyde (MDA). Secondary outcomes include urinary 8-OHdG and F2-isoprostanes, antioxidant enzyme activities, cortisol levels, and gene expression profiles. This study will help to determine whether the supplement can mitigate exercise-induced oxidative stress and support recovery in recreational athletes.

Participants will attend seven in-person visits:

• V0; week 0 (Screening): Informed consent, eligibility check, medical history, anthropometry.
• V1; week 1 (Baseline 1): Pre-intervention samples collection, supplement/placebo dispensation.
• V2; week 1: Exercise test to determine VO₂ max.
• V3; week 3: First treadmill session after 14 days of intervention with the supplement or placebo, blood draw.
• V4; week 3: Urine sample drop-off post-exercise (0-3h and 3-24h).
• V5; week 4 (Baseline 2): Pre-second intervention samples, crossover begins.
• V6; week 6: Second treadmill session, blood draw.
• V7; week 6: Final urine collection post-exercise (0-3h and 3-24h)..

Conditions

Oxidative Stress; Physical Activity; Antioxidant Effect

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: PREVENTION
• Blinding Strategy: QUADRUPLE

Study Groups

Placebo

Participants treated with Microcrystalline Cellulose for 14 days

Group Type: PLACEBO_COMPARATOR

Control Group

Intervention Type: DIETARY_SUPPLEMENT

Participants will take 2 sachets, each containing 340 mg microcrystalline cellulose, and 1.91 g of excipients.

ccPT-SIL-NR Group

Participants treated with pterostilbene, silybin, and nicotinamide riboside for 14 days

Group Type: EXPERIMENTAL

Pterostilbene-silybin-nicotinamide riboside

Intervention Type: DIETARY_SUPPLEMENT

Participants will take 2 sachets, each containing 340 mg of ccPT, silybin and nicotinamide riboside, and 1.91 g of excipients.

Interventions

Pterostilbene-silybin-nicotinamide riboside

Participants will take 2 sachets, each containing 340 mg of ccPT, silybin and nicotinamide riboside, and 1.91 g of excipients.

Intervention Type: DIETARY_SUPPLEMENT

Control Group

Participants will take 2 sachets, each containing 340 mg microcrystalline cellulose, and 1.91 g of excipients.

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

• Male participants between 18 and 50 years of age who are amateur runners.
• Engage in at least 3 continuous running sessions per week, each lasting 60 minutes, which corresponds to a high level of physical activity according to the International Physical Activity Questionnaire (IPAQ).*
• Self-report being able to continuously run for 45 minutes at high intensity without difficulty.
• Provide signed informed consent prior to participation in the study.
• Able to read, write, and speak either Catalan or Spanish.

• High level of physical activity according to the IPAQ: vigorous physical activity (such as running) on at least 3 days per week, with a total energy expenditure ≥1500 MET-min/week.

MET value for vigorous activity = 8 × minutes × days per week.

Exclusion Criteria

• Body Mass Index (BMI) ≤ 18 kg/m² or ≥ 30 kg/m².
• Presence of chronic diseases associated with increased oxidative stress, such as diabetes, hypertension, chronic obstructive pulmonary disease (COPD), or neurodegenerative diseases.
• Personal history of cardiovascular disease, including myocardial infarction, angina pectoris, stroke, or peripheral artery disease.
• Use of antibiotics within 30 days prior to study entry.
• Use of medications or vitamin supplements that may interfere with the study supplement and exceed 100% of the recommended daily intake within 30 days prior to the start of the study.
• Use of polyphenol supplements, herbal extracts, or phytotherapeutic products that may interfere with the study treatment within 30 days prior to study start.
• Alcohol consumption of 4 or more Standard Drink Units (SDUs) per day or 28 SDUs per week.*

*One SDU is defined as 10 grams of alcohol. This corresponds approximately to: 1 glass of wine (120 mL), 1 beer (330 mL), or 1 small spirit (25 mL); 2 SDUs correspond to 1 glass of brandy or liqueur (55 mL), 1 whiskey (70 mL), or a mixed drink (75 mL).

• Active smoker.
• Unintentional weight loss of more than 3 kg in the past 3 months.
• Known food allergies and/or intolerances related to the study products.
• Presence of anemia.
• Presence of chronic gastrointestinal diseases* or cancer.**

*Chronic gastrointestinal diseases include those in an active phase that may interfere with nutrient absorption. Common examples include gastritis, hiatal hernia, Crohn's disease, celiac disease, irritable bowel syndrome, diverticulitis, diverticulosis, chronic constipation, and ulcerative colitis.

**Individuals with a history of cancer may be included only if they are in complete remission at the start of the study.

• Participation in another drug clinical trial or nutritional intervention study within 30 days prior to study inclusion.
• Inability to follow the study guidelines.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Circe, S.L.

UNKNOWN

Sponsor Role: collaborator

Fundació Eurecat

OTHER

Sponsor Role: lead

Responsible Party

Antoni Caimari

Director of the of the Biotechnology Area

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Antoni Caimari, PhD

Role: PRINCIPAL_INVESTIGATOR

Fundació Eurecat

Locations

Fundació Eurecat

Reus, Tarragona, Spain

Site Status: RECRUITING

Countries

Spain

Central Contacts

Antoni Caimari, PhD

Role: CONTACT

antoni.caimari@eurecat.org

+34 977 300 431 ext. 4814

Anna Crescenti, PhD

Role: CONTACT

anna.crescenti@eurecat.org

+34 977 300 431 ext. 4814

Facility Contacts

Antoni Caimari, PhD

Role: primary

antoni.caimari@eurecat.org

+34 977 300 431 ext. 4814

Related Links

http://eurecat.org

Technological Centre of Nutrition and Health. Eurecat\_Reus.

Other Identifiers

PT-SILAOX

Identifier Type: -

Identifier Source: org_study_id